Print

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/38/ariel4-rucaparib-and-recurrent-ovarian-cancer

Clinicaltrials.gov identifier:
NCT02855944 (https://clinicaltrials.gov/show/NCT02855944)

Treatment

Study Contact Information:

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email

The study is open and recruiting at sites in these state: AZ, CA, CO, FL, ME, MI, NY, OH and these countries: Canada, Czechia, Brazil, Hungary, Israel, Italy, Poland, Spain, Ukraine, United Kingdom


About the Study

ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information. 

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Type of Study

ARIEL4 is a randomized, 2-arm, open-label cross-over study. 

What the Study Entails

Patient who qualify for the ARIEL4 trial and enroll, receive the following as part of the study: standard-of-care and study related clinical exams, blood tests, imaging scans of your cancer, lab test results including BRCA and the other biomarker tests, the study medication (rucaparib or chemotherapy) and other assessments. Patients who were treated with chemotherapy on the main study and then experience a worsening of their ovarian cancer may be eligible to receive rucaparib after they discontinue chemotherapy.

Study Sites

Study sites are open in several states in the US and international sites are open as well. For an up-to-date list of study sites, visit the ARIEL4 website

US Sites:

State City Facility Contact Info
Arizona Tucson University of Arizona cancer CenteAllison Wolgast (Study Coordinator) by phone: 1-313-576-8994 or by emailr Yrma Burruel (Study Coordinator) by phone: 1-520-694-9081 or by email
Elizabeth (Jennie) Collins (Study Coordinator) by phone: 1-520-694-9067 or by email
California Monterey Pacific Cancer Care Leslie Hohenbrink (Study Coordinator) by phone: 1-831-375-4105 or by email
Orange University of California Irvine Health Chao Family Comprehensive Cancer Center Anita Wallick (Study Coordinator) by phone: 1-714-456-6191 or by email
Colorado Littleton Rocky Mountain Cancer Center Valerie Apodaca by phone: 1-303-285-5081 or by email
Florida Orlando Florida Hospital Cancer Institute Jane LeBlanc (Study Coordinator) by phone: 1-407-303-2090, ext: 1104286 or by email
Maine Scarborough Maine Medical Center Maine Medical Partners Gynecologic Oncology Robin Donovan (Study Coordinator) by phone: 1-207-396-7089 or by email
Michigan Detroit Wayne State University Allison Wolgast (Study Coordinator) by phone: 1-313-576-8994 or by email
New York Mineola Women's Contemporary Care Associates (WCCA) – Mineola Jennifer Brown (Study Coordinator) by phone: 1-516-663-3115 or by email
Ohio Cincinnati University of Cincinnati Lisa Woeste (Study Coordinator) by phone: 1-513-584-4528 or by email


International Study Sites:

Canada, Czechia, Brazil, Hungary, Israel, Italy, Poland, Spain, Ukraine, United Kingdom


This Study is Open To:

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

This Study is Not Open To:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.